Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease - Perspectives From the CREDO-Kyoto Registry

被引:22
作者
Furukawa, Yutaka [1 ]
Taniguchi, Ryoji [2 ]
Ehara, Natsuhiko [1 ]
Ozasa, Neiko [3 ]
Haruna, Yoshisumi [4 ]
Saito, Naritatsu [3 ]
Doi, Takahiro [3 ]
Hoshino, Kozo [5 ]
Shizuta, Satoshi [3 ]
Morimoto, Takeshi [6 ]
Imai, Yukiko [7 ]
Teramukai, Satoshi [7 ]
Fukushima, Masanori [7 ]
Kita, Toru [3 ]
Kimura, Takeshi [3 ]
机构
[1] Gen Hosp, Kobe City Med Ctr, Div Cardiol, Chuo Ku, Kobe, Hyogo 6500046, Japan
[2] Hyogo Prefecture Amagasaki Hosp, Div Cardiol, Amagasaki, Hyogo, Japan
[3] Kyoto Univ Hosp, Dept Cardiovasc Med, Kyoto 606, Japan
[4] Hirakata Kohsai Hosp, Div Cardiol, Dept Med, Hirakata, Osaka, Japan
[5] Nagai Hosp, Div Cardiol, Tsu, Mie, Japan
[6] Kyoto Univ, Grad Sch Med, Ctr Med Educ, Kyoto, Japan
[7] Translat Res Informat Ctr, Kobe, Hyogo, Japan
关键词
Coronary artery disease; Mortality; Revascularization; Statins;
D O I
10.1253/circj.CJ-08-0293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The importance of statins in cardiovascular prevention has been demonstrated ill various patient subsets. This study aimed to evaluate the effects of statins on long-term Outcomes of Japanese patients undergoing first coronary revascularization. Methods and Results A total of 9,225 patients Undergoing their first coronary revascularizations during 2000-2002 were divided into 2 groups according to the use of statins at discharge; patients with acute Myocardial infarction Were not included. Statins was administered to only 28.5% (n=2,630) of the patients. The median follow-up period was 3.5 years. Patients on statin therapy showed lower all-cause (5.2% vs 10.0%; p<0.0001) and Cardiovascular (3.2% vs 6.2%; p<0.0001) mortality than those Without statins (n=6,595) by Kaplan-Meier analysis and log-rank test. After adjustment by mutivariate analysis according to 29 variables, statin therapy remained as all independent predictor of reduced all-cause (relative risk ratio (RR) 0.71, 95% confidence interval (CI) 0.59-0.86, p=0.0005) and cardiovascular (RR 0.72, 95% CI 0.56-0.91, p=0.0067) mortality. The validity of RR of statin therapy in multivariate analysis was further confirmed by risk adjustment using propensity scores (all-cause mortality: propensity-adjusted RR 0.70, 95% CI 0.58-0.85, p=0.0003 cardiovascular mortality: propensity-adjusted RR 0.70, 95% CI 0.54-0.89, p=0.0038). Conclusions Statin therapy started at hospital discharge was associated with increased chance Of survival ill Japanese patients Undergoing their first coronary revascularization. (Circ J 2008; 72: 1937-1945)
引用
收藏
页码:1937 / 1945
页数:9
相关论文
共 37 条
[1]   Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator [J].
Alvarez-Sabin, Jose ;
Huertas, Rafael ;
Quintana, Manolo ;
Rubiera, Marta ;
Delgado, Pilar ;
Ribo, Marc ;
Molina, Carlos A. ;
Montaner, Joan .
STROKE, 2007, 38 (03) :1076-1078
[2]   Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery [J].
Arora, R ;
Sowers, JR ;
Saunders, E ;
Probstfield, J ;
Lazar, HL .
JOURNAL OF CARDIAC SURGERY, 2006, 21 (02) :198-204
[3]   Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features [J].
Brener, SJ ;
Lytle, BW ;
Casserly, IP ;
Schneider, JP ;
Topol, EJ ;
Lauer, MS .
CIRCULATION, 2004, 109 (19) :2290-2295
[4]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[5]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[6]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[7]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[8]  
2-B
[9]   The initial management of stable angina in Europe, from the Euro Heart Survey - A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina [J].
Daly, CA ;
Clemens, F ;
Sendon, JLL ;
Tavazzi, L ;
Boersma, E ;
Danchin, N ;
Delahaye, F ;
Gitt, A ;
Julian, D ;
Mulcahy, D ;
Ruzyllo, W ;
Thygesen, K ;
Verheugt, F ;
Fox, KM .
EUROPEAN HEART JOURNAL, 2005, 26 (10) :1011-1022
[10]   Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study [J].
Deedwania, Prakash ;
Barter, Philip ;
Carmena, Rafael ;
Fruchart, Jean-Charles ;
Grundy, Scott M. ;
Haffner, Steven ;
Kastelein, John J. P. ;
LaRosa, John C. ;
Schachner, Holly ;
Shepherd, James ;
Waters, David D. .
LANCET, 2006, 368 (9539) :919-928